Role of Multimodality Imaging in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

Seminars in Roentgenology

Volumn 47, Issue 3, 2012, Pages 253-261

  Koss, Elana ^a   Garcia, Mario J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE BLOCKING AGENT; GADOLINIUM; UNCLASSIFIED DRUG; VASODILATOR AGENT;

AMYLOIDOSIS; ARTICLE; CARDIAC IMAGING; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG MECHANISM; ECHOCARDIOGRAPHY; FABRY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART SURGERY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MITRAL VALVE DISEASE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; SARCOIDOSIS; SCREENING TEST; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

CARDIAC-GATED IMAGING TECHNIQUES; CONTRAST MEDIA; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART SEPTUM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, CINE; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 84861658762     PISSN: 0037198X     EISSN: 15584658     Source Type: Journal    
DOI: 10.1053/j.ro.2012.01.002     Document Type: Article

References (66)

1. Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the pediatric cardiomyopathy registry. Circulation 2007, 115:773-781.
2. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus panel on hypertrophic cardiomyopathy: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice guidelines. J Am Coll Cardiol 2003, 42:1687-1713.
3. Keren A., Syrris P., McKenna W.J. Hypertrophic cardiomyopathy: The genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008, 5:158-168.
4. Davies M.J. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br Heart J 1984, 51:361-363.
5. Caselli S., Pelliccia A., Maron M., et al. Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol 2008, 102:616-620.
6. Maron B.J. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002, 287:1308-1320.
7. Prasad K., Atherton J., Smith G.C., et al. Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart 1999, 82(suppl 3):III8-III15.
8. Olszewski R., Timperley J., Szmigielski C., et al. The clinical applications of contrast echocardiography. Eur J Echocardiogr 2007, 8:S13-S23.
9. Kramer C.M., Barkhausen J., Flamm S.D., et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: Board of Trustees Task Force on Standardized Protocols. J Cardiovasc Magn Reson 2008, 10:35.
10. Maron M.S., Maron B.J., Harrigan C., et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009, 54:220-228.
11. Moon J.C., Fisher N.G., McKenna W.J., et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004, 90:645-649.
12. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112:855-861.
13. Maron M.S., Hauser T.H., Dubrow E., et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007, 100:1293-1298.
14. Kwon D.H., Setser R.M., Thamilarasan M., et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008, 94:1295-1301.
15. Mark D.B., Berman D.S., Budoff M.J., et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010, 55:2663-2699.
16. Orakzai S.H., Orakzai R.H., Nasir K., et al. Assessment of cardiac function using multidetector row computed tomography. J Comput Assist Tomogr 2006, 30:555-563.
17. Dewey M., Müller M., Eddicks S., et al. Evaluation of global and regional left ventricular function with 16-slice computed tomography, biplane cine ventriculography, and two dimensional transthoracic echocardiography: comparison with magnetic resonance imaging. J Am Coll Cardiol 2006, 48:2034-2044.
18. Nagueh S.F., Bachinski L.L., Meyer D., et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001, 104:128-130.
19. Cardim N., Perrot A., Ferreira T., et al. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol 2002, 90:128-132.
20. Kato T.S., Noda A., Izawa H., et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 2004, 110:3808-3814.
21. Serri K., Reant P., Lafitte M., et al. Global and regional myocardial function quantification by two-dimensional strain: Application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006, 47:1175-1181.
22. Carasso S., Yang H., Woo A., et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: Novel concepts and implications for clinical status. J Am Soc Echocardiogr 2008, 21:675-683.
23. Nagueh S.F., Bierig S.M., Budoff M.J., et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2011, 24:473-498.
24. Kim Y.J., Choi B.W., Hur J., et al. Delayed enhancement in hypertrophic cardiomyopathy: Comparison with myocardial tagging MRI. J Magn Reson Imaging 2008, 27:1054-1060.
25. Nishimura R.A., Appleton C.P., Redfield M.M., et al. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: A simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 1996, 28:1226-1233.
26. Nagueh S.F., Lakkis N.M., Middleton K.J., et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999, 99:254-261.
27. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107-133.
28. Paraskevaidis I.A., Panou F., Papadopoulos C., et al. Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: A tissue Doppler imaging and two-dimensional strain study. Heart 2009, 95:483-489.
29. Grigg L.E., Wigle E.D., Williams W.G., et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992, 20:42-52.
30. Klues H.G., Maron B.J., Dollar A.L., et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85:1651-1660.
31. Sherrid M.V., Wever-Pinzon O., Shah A., et al. Reflections of inflections in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009, 54:212-219.
32. Schulz-Menger J., Abdel-Aty H., Busjahn A., et al. Left ventricular outflow tract planimetry by cardiovascular magnetic resonance differentiates obstructive from non-obstructive hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2006, 8:741-746.
33. O'Brien K.R., Cowan B.R., Jain M., et al. MRI phase contrast velocity and flow errors in turbulent stenotic jets. J Magn Reson Imaging 2008, 28:210-218.
34. Alkadhi H., Desbiolles L., Stolzmann P., et al. Mitral annular shape, size, and motion in normals and in patients with cardiomyopathy: Evaluation with computed tomography. Invest Radiol 2009, 44:218-225.
35. Cecchi F., Olivotto I., Gistri R., et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003, 349:1027-1035.
36. Petersen S.E., Jerosch-Herold M., Hudsmith L.E., et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 2007, 115:2418-2425.
37. Sipola P., Lauerma K., Husso-Saastamoinen M., et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology 2003, 226:129-137.
38. Cannon R.O., Dilsizian V., O'Gara P.T., et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991, 83:1660-1667.
39. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
40. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:2156-2164.
41. Maron M.S., Harrigan C., Buros J., et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008, 1:184-191.
42. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
43. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 3:51-58.
44. Teraoka K., Hirano M., Ookubo H., et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004, 22:155-161.
45. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts Major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
46. Jung W.I., Sieverding L., Breuer J., et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998, 97:2536-2542.
47. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003, 41:1776-1782.
48. Maron B.J., Seidman J.G., Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44:2125-2132.
49. Ho C.Y., Carlsen C., Thune J.J., et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009, 2:314-321.
50. Maron M.S., Olivotto I., Harrigan C., et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011, 124:40-47.
51. Moon J.C., Mogensen J., Elliott P.M., et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005, 91:1036-1040.
52. Germans T., Wilde A.A., Dijkmans P.A., et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006, 48:2518-2523.
53. Valeti U.S., Nishimura R.A., Holmes D.R., et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007, 49:350-357.
54. Okayama S., Uemura S., Soeda T., et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr 2010, 4:62-65.
55. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
56. McKenna W.J., Behr E.R. Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart 2002, 87:169-176.
57. Nagueh S.F., Mahmarian J.J. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2006, 48:2410-2422.
58. Hansen M.W., Merchant N. MRI of hypertrophic cardiomyopathy: Part 2, differential diagnosis, risk stratification, and posttreatment MRI appearances. Am J Roentgenol 2007, 189:1344-1352.
59. Fattori R., Rocchi G., Celletti F., et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998, 136:824-830.
60. Vogelsberg H., Mahrholdt H., Deluigi C.C., et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008, 51:1022-1030.
61. Vignaux O. Cardiac sarcoidosis: Spectrum of MRI features. Am J Roentgenol 2005, 184:249-254.
62. Whyte G.P., George K., Sharma S., et al. The upper limit of physiological cardiac hypertrophy in elite male and female athletes: The British experience. Eur J Appl Physiol 2004, 92:592-597.
63. Petersen S.E., Selvanayagam J.B., Francis J.M., et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005, 7:551-558.
64. Hansen M.W., Merchant N. MRI of hypertrophic cardiomyopathy: Part I, MRI appearances. Am J Roentgenol 2007, 189:1335-1343.
65. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24:2151-2155.
66. O'Hanlon R., Assomull R.G., Prasad S.K. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep 2007, 9:51-56.